Overview
EDDING GENOR (6998)
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical...
- Open
- 1.570
- High
- 1.575
- Low
- 1.520
- Prev. Close
- 1.550
- Volume
- 764.50K
- Turnover
- 1.20M
- Avg Price
- 1.565
- Bid/Ask Ratio
- -35.48%
- Amplitude
- 3.55%
- 52wk High
- 3.900
- Volume Ratio
- 1.34
- Turnover Ratio
- 0.04%
- 52wk Low
- 1.420
- HK Mkt Cap
- 3.09B
- Market CapHKD
- 3.09B
- P/ETTM
- 12.24
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- 0.128
- EPSDynamic
- -0.0771
- EPSStatic
- --
- BVPS
- 2.33
- P/B
- 0.67
- HK Shares
- 1.97B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.97B
- Min lot size
- 500
- Currency
- HKD
EDDING GENOR Analyst Rating
View moreForecast & Rating
Aug 31, 2023- Strong buy0.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell100.00%
- Strong buy
- 0
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 1
Daily Events
- Nov, 3
Edding Genor fell 4.27% to HK$1.570, spiking to HK$1.640 in the morning session before sliding to an intraday low of HK$1.525 in the afternoon, on 1.48 million shares and HK$2.32 million turnover, a thin 0.08% turnover rate that amplified the move. Buybacks have continued: 500,000 shares for HK$810,000 on November 2 and another 500,000 for HK$785,000 on October 28, after several similar-sized repurchases from October 20, yet the bid offered limited support. ESMO 2026 first-in-human data showed GB268 monotherapy at a 19% response rate in the phase I breast cancer cohort, still early-stage. Q2 2026 revenue of HK$504.0 million fell 18.99% yoy, with a net loss of HK$38.0 million against a year-earlier profit, down 160.57%, net margin -7.54%, PE 12.27x and PB 0.67x. The stock is down 45.86% YTD, 59.74% below its 52-week high of HK$3.90 and only 10.56% above the HK$1.42 low, sitting under its MA20 of HK$1.641 and MA60 of HK$1.653. Continuous buybacks and a 0.67x PB offer some cushion, though.
- Oct, 26
After ESMO 2026 first-in-human Phase I data for GB268, Edding Genor still faded an early rally, closing at HK$1.540, about 5.2% below the prior close of HK$1.625, having touched HK$1.635 at 09:58 BJ and HK$1.535 at 15:35 BJ. The 19% response rate in the Phase I breast cancer cohort and NMPA clearance for a Phase II colorectal trial contrast with Q2 2026 revenue of HK$504.0m (-18.99% yoy), a net loss of HK$38.0m (-160.57% yoy) and EPS of -0.0191. Buybacks were frequent, including 500,000 shares for HK$829,000 on October 20 alone, without lifting the stock. Price sits below MA20 of 1.671 and MA60 of 1.66, down 45% YTD, 59.1% under the 52-week high of HK$3.90 and 12.32% above the 52-week low of HK$1.42; PB is 0.69 and market cap HK$3.14bn. Though turnover of just 0.02% points to thin liquidity that can amplify intraday swings.
- Oct, 7
Edding Genor reversed from its intraday high to close at HK$1.665, down about 2.1% from the prior HK$1.700, sliding from 1.700 in the morning session and touching 1.665 in the afternoon on just 243,500 shares, a turnover ratio of 0.01%. The pressure traces to fundamentals: the company swung to an H1 net loss of RMB 65.88 million with revenue down 23.1% to RMB 872.73 million, while Q2 net profit of -HK$37.99 million fell 160.6% year on year and the Jing Zhu Da sub-licensing deal collapsed after upstream license termination. Offsetting flows include continuous buybacks at HK$1.85-1.92 since October, a chairman plan to raise his stake, and August NMPA clearance for a Phase Ib/II trial of the trispecific breast cancer antibody GB268. The shares remain below MA20 (1.696) and MA60 (1.703), down 42.59% year to date and 61.64% below the 52-week high of HK$4.34. Though buybacks and pipeline progress provide partial offset.
- Sep, 25
Edding Genor closed at HKD 1.665, opening down 0.6% before staging a dip-recovery pattern, hitting a fresh 52-week low of HKD 1.65 and rebounding to HKD 1.70. The stock has fallen 64.04% from its 52-week high of HKD 4.63 and is down 42.59% year-to-date, currently trading below both its MA20 (HKD 1.682) and MA60 (HKD 1.722). Fundamentals weakened further with H1 2026 net loss of ~HKD 75 million versus a year-ago profit, while revenue dropped over 18%. The company has been actively repurchasing shares around HKD 1.85-1.92, though the dramatic intraday rebound signals bargain-hunting support at these levels.
- Sep, 24
Edding Genor (6998.HK) fell 5.3% in the morning session to HKD 1.70, as its H1 2026 net loss guidance of RMB 60-70 million (swinging from a year-ago profit) and an 18%+ revenue decline weighed on sentiment. The stock opened at HKD 1.79 and drifted to an intraday low of HKD 1.70, near its 52-week low of HKD 1.42, with YTD losses reaching 41.4%. The current price sits above its 20-day MA (HKD 1.674) but below the 60-day MA (HKD 1.725), indicating near-term support amid a medium-term downtrend. Recent share buybacks (up to 10% of issued shares) and the chairman's stake-boosting plan, along with NMPA approval for a Phase Ib/II trial of its trispecific breast cancer antibody GB268, provided some offset to the earnings warning.
News
PUBT · Shanghai Chicmax Files Next-Day Disclosure With HKEX Announcing Share Buyback
PUBT · Edding Genor Wins China Approval for GB268 Cancer Trials
PUBT · FIH Mobile Files HKEX Next Day Disclosure Return Announcing Share Buyback
PUBT · Antengene Files Next-Day Disclosure Return With HKEX Announcing Share Buyback
PUBT · Edding Genor Files Next-Day Disclosure With HKEX Announcing Share Buyback
PUBT · Shuangdeng Group Files Next-Day Disclosure Return With HKEX Announcing Share Buyback
